Key keywords: Doximity Q2 2026 earnings, NYSE:DOCS, DOCS stock performance, healthcare professional network, digital health platform, Q2 2026 revenue beat, physician engagement metrics, clinical AI tools On August 12, 2026, leading U.S. healthcare professional network Doximity (NYSE:DOCS) released its second quarter calendar year 2026 financial results, surpassing analyst expectations across core revenue and earnings metrics to extend its steady growth trajectory in the digital health space. The company reported total Q2 2026 revenue of $137.2 million, representing a 21% year-over-year increase and beating the consensus analyst estimate of $128.1 million by 7.1%. Non-GAAP diluted earnings per share came in at $0.15, 25% above the market consensus forecast of $0.12, marking the 12th consecutive quarter that Doximity has outperformed Wall Street revenue expectations. Revenue growth was driven by two core business segments: its pharmaceutical marketing and advertising solutions arm, which grew 24% year-over-year to $89.4 million, and its clinical workflow subscription services, which rose 18% year-over-year to $47.8 million. The marketing segment’s strong performance was fueled by increased demand from biopharmaceutical clients seeking targeted, compliant access to U.S. healthcare providers, as Doximity’s platform now reaches 85% of all practicing U.S. physicians and 92% of active medical residents. Monthly active users (MAUs) on the platform hit 2.4 million in Q2, up 9% year-over-year, with average daily active user session duration rising 12% to 18 minutes, reflecting deepening user engagement. Doximity’s recently launched AI-powered clinical documentation tool also saw explosive adoption, with paid user counts jumping 3x quarter-over-quarter to 412,000, as providers seek to reduce administrative burdens associated with electronic health record (EHR) entry. During the earnings call, CEO Jeff Tangney noted that the AI tool has cut average provider note-taking time by 32% for early adopters, driving high retention rates of 94% for the product line. For the third quarter of CY2026, Doximity issued guidance of $141 million to $144 million in total revenue, representing 19% to 21% year-over-year growth, and raised its full-year CY2026 revenue guidance by 2% to a range of $548 million to $555 million, up from its prior forecast of $537 million to $544 million. Following the earnings release, DOCS stock rose 7.2% in pre-market trading, as investors reacted positively to the top-line beat and upward guidance revision.